1. Sadock BJ, Sadock VA. Kaplan & Sadock’s comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009, pp. 1432-1629.
2. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neu-ropsychopharmacol Biol Psychiatry. 1998;22(1):1-33.
3. Monji A. The neuroinflammation hypothesis of psychiatric disorders. Seishin Shinkeigaku Zasshi. 2012;114(2):124-33. [Article in Japa-nese]
4. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased inter-leukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):75-83.
5. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Phar-macol. 2012;7(3):656-64.
6. Licino J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic pa-tients. Am J Psychiatry. 1993;150(9):1408-10.
7. McAllister CG, Van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL. Increases in CSF levels of interleukin–2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152(9):1291-7.
8. Müller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of pa-raniod schizophrenic patients. Eur Psychiatry. 1997;12(6):294-9.
9. Van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G (ed) Current Update in Psychoimmunology Springer Verlag Wien: NY, 1997, pp. 51-55.
10. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci. 2004;254(1):14-22.
11. Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):149-51.
12. Müller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin Investig Drugs. 2004;13(8):1033-44.
13. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000;293(2):417-25.
14. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy com-pared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029-34.
15. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1997;247(6):308-13.
16. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpé S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998;32(1):9-15.
17. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. IL-2 and IL-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141-52.
18. Yermakova A, Banion MK. Cyclooxygenases in the Central Nervous System: implication for treatment of neurogical disorders. Curr Pharm Des. 2000;6(17):1755-6.
19. Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizo-phrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011;132(1):96-110.
20. Hochberg MC. COX-2 selective inhibitors in the treatment of arthri-tis: a rheumatologist perspective. Curr Top Med Chem. 2005;5(5):443-8.
21. McGeer PL. COX –2 inhibitors: rationale and therapeutic potential for Alzheimer’s disease. Drug Aging. 2000;17(1):1-11.
22. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Ab-basi SH, Behnam B. Celecoxib as adjunctive therapy in schizophre-nia: a double-blind, randomized and placebo-controlled trial. Schiz-ophr Res. 2007;90(1-3):179-85.
23. Mizuno M, Sotoyama H, Narita E, Kawamura H, Namba H, Zheng Y, Eda T, Nawa H. A cyclooxygenase-2 inhibitor ameliorates behav-ioral impairments induced by striatal administration of epidermal growth factor. J Neurosci. 2007;27(38):10116-27.
24. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57(12):1594-6.
25. Stolk P, Souverein PC, Leufkens HG, Weil JG, Egberts AC, Heerdink ER. The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. Pharma-copsychiatry. 2007;40(3):111-5.
26. Ginovart N, Kapur S. Role of dopamine d(2) receptors for antipsy-chotic activity. Handb Exp Pharmacol. 2012;(212):27-52.
27. Partitt K. Martindale: the complete drug reference. 32nd ed. Massa-chusetts: Pharmacological Press; 1999. pp. 63-6, 657-60.
28. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immuno-modulatory effects of clozapine and their clinical implications: what have we learned so far?. Schizophr Res. 2012;140(1-3):204-13.
29. Meltzer HY. Update on Typical and Atypical Antipsychotic Drugs. Annu Rev Med. 2013;64:393-406.
30. Hardman IG, Limbard LE. Goodman & Gilman’s the Pharmacologi-cal Basis of Therapeutics. 10th ed. New York: Mc Graw – Hill; 2001. pp. 485-500, 715.
31. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as tar-gets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1572-86.
32. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schiz-ophrenia and response to antipsychotics: a review. Schizophr Res. 2011;133(1–3):54-62.
33. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclo-oxygenase-2 selective in-hibitors aggravate kainic and induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999; 843(1-2):118-29.
34. Lantz MS, Giambanco V. Acute onset of auditory hallucination after initiation of celecoxib therapy. Am J Psychiatry. 2000;157(6):1022-3.
35. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276.
36. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23(1):99-110.
37. Kianmanesh S, Jenaabadi H. The study of difference between the fre-quency of positive and negative symptoms of schizophrenia in people with different cultural backgrounds. Glob J Scientific Res. 2014;2(5):124-7.
38. Müller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 in-hibitors--a possible new approach for the treatment of psychiatric dis-orders. Pharmacopsychiatry. 2004;37(6):266-9.
39. Bresee CJ, Delrahim K, Maddux RE, Dolnak D, Ahmadpour O, Ra-paport MH. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol. 2006;9(3):343-8.
40. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, Kanba S. The effect of atypical antipsychotics, perospirone,
ziprasidone and quetiapine on microglial activation induced by inter-feron-gamma. Prog Neuropsychopharmacol Biol Psychia-try. 2008;32(1):42-8.
41. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperi-dol plasma concentrations and haloperidol clearance. Psychopharma-cology (Ber). 1986;90(4):468-70.
42. Dysken MW, Cumming RJ, Channon RA, Davis JM. Drug interac-tion between ascorbic acid and fluphenazine. JAMA. 1979;241(19):2008.
43. Kulhanek F, Linde OK, Meisenberg G. Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet. 1979;1(8152):1130-1.
44. Bowen S, Taylor KM, Gibb IA. Effect of coffee and tea on blood levels and efficacy of antipsychotic drugs. Lancet 1981;1(8231):1217-18.
45. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414-9.
46. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharma-cother. 2006;7(7):837-48.